Benzinga | Dec 22, 2021 07:30AM EST

Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $350

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $390 to $350.